Findings from COLLIGO-HCM reinforce Camzyos’ efficacy and safety profile in reducing left ventricular outflow tract (LVOT) obstruction and improving symptom burden in a racially diverse, global ...

Cytokinetics has set out to prove that aficamten is a threat to Bristol Myers Squibb’s $13.1 billion heart disease drug Camzyos, and a new analysis gives the first shot at an apples-to-apples ...

SHANGHAI, China and PRINCETON, N.J., June 26, 2023 (GLOBE NEWSWIRE) -- LianBio (Nasdaq: LIAN), a biotechnology company dedicated to bringing innovative medicines to patients in China and other Asian ...

Hypertrophic cardiomyopathy is a heart condition where the heart muscle becomes abnormally thick. This makes it harder for the heart to work correctly. Obstructive hypertrophic cardiomyopathy (oHCM) ...

PRINCETON, N.J.--(BUSINESS WIRE)--Bristol Myers Squibb (NYSE: BMY) today announced that the U.S. Food and Drug Administration (FDA) approved the supplemental New Drug Application (sNDA) to add ...

Camzyos is the first and only FDA-approved cardiac myosin inhibitor that specifically targets the source of obstructive HCM PRINCETON, N.J.--(BUSINESS WIRE)--Bristol Myers Squibb (NYSE: BMY) today ...

Camzyos (mavacamten) is a brand-name capsule that’s prescribed for obstructive hypertrophic cardiomyopathy in adults. It has a boxed warning about the risk of heart failure. To help manage this, the ...

Factors affecting Camzyos cost include your treatment plan, insurance coverage, pharmacy, and whether Camzyos has a savings program that you qualify for. The Camzyos Co-Pay Program is available for ...

Eligible patients taking Camzyos in the maintenance phase now only require twice-yearly echocardiogram monitoring. The Food and Drug Administration (FDA) has updated the labeling for Camzyos ® ...

Bristol Myers Squibb is stepping up promotion of its $13.1 billion heart disease drug Camzyos, launching the first branded TV spot as it seeks to penetrate the market ahead of the anticipated arrival ...

CAMZYOS reduces systolic contraction and can cause heart failure or significantly reduce ventricular function. Patients who experience a serious intercurrent illness (eg, serious infection) or ...

Camzyos is an oral, selective allosteric and reversible inhibitor of cardiac myosin. The Food and Drug Administration (FDA) has approved Camzyos ™ (mavacamten) for the treatment of adults with ...